Elicitation of expert prior opinion to design the BARJDM trial in juvenile dermatomyositis
Authors' conclusion
Experts currently think that baricitinib is superior to MTX for the treatment of JDM, although there is uncertainty around this.
Study context
- Population
- UK paediatric rheumatology consultants with expertise in JDM, leading active NHS clinics for this disease
- Participants
- 10 UK paediatric rheumatology consultants
- Comparison
- Baricitinib vs MTX, with identical glucocorticoids (GC) schedules
- Outcome
- Expert prior probability that a patient would achieve clinically inactive disease off GC
- Follow-up
- Within 12 months
Methodological detailsBayesian prior elicitation meeting
- Bayesian prior elicitation meeting
Main finding
As reported in the abstract
Most likely probability of clinically inactive disease off GC (consensus expert prior)
Baricitinib
0.55
most likely probability
MTX
0.23
most likely probability
Original publication
Elicitation of expert prior opinion to design the BARJDM trial in juvenile dermatomyositis. Rheumatology (Oxford). Published 29 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →